Danaher

DHR

Market cap $142B

Investors need to pay close attention to DHR stock based on the movements in the options market lately.

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mar Vista's U.S. Quality Premier strategy returned +10.15% net-of-fees in the second quarter of 2026. GE Aerospace, Alphabet and Taiwan Semiconductor Manufacturing were among the portfolio's top contributors for the quarter, appreciating +31.70%, + 23.25%, and + 41.57%, respectively. During the quarter, we initiated new investments in ASML Holding and exited our position in Intuit.

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.

Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (NYSE: DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) and Uganda through Save the Children, the International Rescue Committee (IRC) and the World Food Program USA in support of the World Food Programme (WFP). The funding will be distributed across the three organizations to enable rapid, flexible response to evolving conditions on the ground.

Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in Merck (MRK).